A Polyphenol-Rich Extract From Muscadine Grapes Inhibits Triple-Negative Breast Tumor Growth.


Journal

Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834

Informations de publication

Date de publication:
Historique:
entrez: 25 6 2020
pubmed: 25 6 2020
medline: 31 7 2021
Statut: ppublish

Résumé

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that tends to affect young women and has a high propensity to metastasize. No targeted treatments are available for this type of breast cancer due to a lack of estrogen or progesterone receptors or overexpression of human epidermal growth factor receptor type 2 overexpression. Currently, patients have no therapeutic options once standard of care is complete, indicating a need for safe and effective therapies to slow or prevent the progression of TNBC to metastatic disease. Studies showed that isolated polyphenols or polyphenol-rich muscadine grape extracts polyphenols inhibit the proliferation of various cancer cells including breast cancer. A proprietary muscadine grape extract (MGE) was administered to nude mice with human MDA-MB-231 TNBC atumors for 4 weeks to determine the effect of the extract on tumor growth. MGE decreased tumor volume in association with a reduction in the proliferative markers Ki67 and cyclin D1. To determine the molecular mechanisms for the MGE-induced reduction in tumor growth, mouse 4T1, MDA-MB-231, or human BT-549 TNBC cells were treated with MGE, and various signaling pathways were investigated. MGE reduced c-Met, differentially abrogated ERK/MAPK and AKT signaling, and decreased a downstream targets of ERK/MAPK and AKT pathways, cyclin D1. Cyclin D1 reduction was associated with retinoblastoma activation and cell cycle arrest in MDA-MB-231 TNBC cells. MGE-regulated molecular signaling pathways were functionally associated with a dose-dependent reduction in cell proliferation. The pluripotency of MGE and high index of safety and tolerability suggest that the extract may serve as a therapeutic to reduce TNBC progression to metastatic disease.

Identifiants

pubmed: 32578460
doi: 10.1177/1534735420917444
pmc: PMC7315667
doi:

Substances chimiques

Plant Extracts 0
Polyphenols 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1534735420917444

Subventions

Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States

Références

Biochim Biophys Acta. 2011 Nov;1813(11):1978-86
pubmed: 21440011
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
pubmed: 22128289
Cancer Treat Rev. 2018 Jan;62:110-122
pubmed: 29202431
Oncogene. 2008 Feb 14;27(8):1106-13
pubmed: 17724476
Prostate. 2015 Oct;75(14):1518-25
pubmed: 26012728
Discov Med. 2014 May;17(95):275-83
pubmed: 24882719
Breast Cancer Res. 2015 Apr 08;17:52
pubmed: 25887320
Cancer. 2010 Jun 1;116(11):2549-59
pubmed: 20336785
Cell Signal. 2008 Apr;20(4):581-9
pubmed: 18023328
Carcinogenesis. 2014 Oct;35(10):2321-30
pubmed: 25023990
Prim Care Companion CNS Disord. 2011;13(2):
pubmed: 21977340
Mol Cancer. 2018 Feb 19;17(1):34
pubmed: 29455658
Trends Biochem Sci. 2011 Jun;36(6):320-8
pubmed: 21531565
Front Oncol. 2012 Aug 07;2:88
pubmed: 22891162
J Cell Sci. 2008 Dec 1;121(Pt 23):3853-7
pubmed: 19020303
Oncol Rep. 2015 Jul;34(1):375-81
pubmed: 25997470
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Ther Adv Med Oncol. 2017 Jul;9(7):493-511
pubmed: 28717401
Mol Cancer. 2018 Jul 25;17(1):104
pubmed: 30045773
Oncogene. 2002 Aug 15;21(36):5515-28
pubmed: 12165850
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Mod Pathol. 2011 Feb;24(2):157-67
pubmed: 21076464
Breast Cancer (Auckl). 2015 Sep 01;9(Suppl 1):23-34
pubmed: 26380552
Nat Rev Clin Oncol. 2012 May 08;9(6):314-26
pubmed: 22566105
J Chromatogr A. 2012 Jun 1;1240:96-103
pubmed: 22520637
Mol Cell Biol. 2002 Nov;22(22):7842-52
pubmed: 12391153
J Agric Food Chem. 2006 Jul 26;54(15):5336-43
pubmed: 16848514
Mol Cancer. 2007 Apr 02;6:24
pubmed: 17407548
Oncotarget. 2016 Aug 30;7(35):56767-56780
pubmed: 27462923
Heliyon. 2019 Jan 16;5(1):e01128
pubmed: 30705983
PLoS One. 2013 Nov 12;8(11):e78641
pubmed: 24265703
Breast Cancer Res Treat. 2009 May;115(2):423-8
pubmed: 18543098
Food Nutr Res. 2017 Dec 10;61(1):1412795
pubmed: 29249924
Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
pubmed: 19596646
J Cancer. 2011;2:324-8
pubmed: 21716849
Oncol Rep. 2011 Jul;26(1):177-84
pubmed: 21503582
Oncogene. 2001 Apr 30;20(19):2390-400
pubmed: 11402335
Genes Dev. 2002 Jun 1;16(11):1356-70
pubmed: 12050114
Anal Biochem. 2014 Dec 15;467:1-3
pubmed: 25193447
Cancer Res. 2007 Sep 1;67(17):8396-405
pubmed: 17804756
Int J Cancer. 1994 May 1;57(3):353-61
pubmed: 8168995
Cold Spring Harb Perspect Biol. 2015 Dec 01;7(12):
pubmed: 26626938

Auteurs

Marianne Collard (M)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Patricia E Gallagher (PE)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

E Ann Tallant (EA)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH